Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From David Ruch
Personalized medicine is becoming the hallmark of care in oncology, but its use is also increasing in other therapeutic areas including inflammation, respiratory, infectious diseases and central nervous system disorders, as scientific understanding of these diseases advances. The expansion of companion diagnostics beyond oncology has impacts on dealmaking, clinical practice and the R&D pipeline.
inVentiv Health Consulting conducted a survey of 85 physicians (oncologists, n = 30; and non-oncologists, n = 55) in February 2017 to explore the views of physicians regarding the role of biomarkers and companion diagnostics in clinical practice.